Cantor Fitzgerald Reiterates Overweight on Pliant Therapeutics, Maintains $63 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $63 price target.
August 22, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $63.
The reiteration of an Overweight rating by a reputable analyst like Pete Stavropoulos from Cantor Fitzgerald is a positive signal for Pliant Therapeutics. The maintained price target of $63 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100